JPH1124010A - Method of manufacturing contact lens for extended releasing medicine visual acuity correction and extended releasing medicine agent - Google Patents

Abstract

PROBLEM TO BE SOLVED: To make it possible to add an extended releasability of medicine which is inexpensive and continuable for a sufficient time irrespective of a material of a contact lens by preparing a finely powered or gelling extended releasing agent for medicine from polymer and adhering it on a part of a contact lens. SOLUTION: A finely-powdered or gelling extended medicine-releasing agent is prepared from at least one kind of polymer selected from poly-hydroxyalkyl (metha) acrylate, poly-vinyl-pyrrolidonne, poly-dimethyl-acrylamine, and hyaluronic acid sodium, and is adhered on a part of a contact lens. Since the extended-medicine-releasing agent is obtained from solving a polymer in aqueous solution of desired medicine, it is inexpensive. In order to sufficiently improve wear-feeling of a finally obtained contact lens, a weight-average molecular weight of a polymer is preferred to the 10000 or more, more preferably, 20000 or more, and for an excellently effective extended reliability of medicine, it is preferred to be not more than 2000000, preferably not more than 1000000.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

[0001] The present invention relates to a method for producing a contact lens for drug-controlled visual acuity correction and a drug sustained-release agent used therefor. More specifically, the present invention relates to a method for attaching a fine powder or gel of a drug solution as a sustained-release agent to a contact lens for vision correction to impart sustained drug release to the contact lens, and a drug sustained-release agent used for the method.

[0002]

2. Description of the Related Art Conventionally, as a contact lens provided with a desired drug sustained release property, for example, a drug is contained in a contact lens formed using a material that is gradually soluble in tears, and a convex surface is formed on the contact lens. A corneal disease treatment device in the form of a contact lens in which a layer that is hardly soluble or insoluble in tears is formed.
No. 7-27457), and a contact lens formed by molding a long-acting polymer hydrogel formulation containing a drug into a desired shape (Japanese Patent Application Laid-Open No. 62-103029).

However, in order to manufacture the contact lens-shaped therapeutic device for corneal diseases, specific compounds such as cellulose, starch, polyvinylpyrrolidone, and sodium alginate must be used as a material containing a drug. Generally, such a contact lens-shaped therapeutic device for corneal disease cannot be produced from a polymer generally used for a contact lens.

[0004] In addition, the polymer for the specific effect hydrogel formulation for producing the contact lens is crosslinked by all types of crosslinkable compounds. It is not usable.

[0005] As described above, the material is a conventional one which has been used in the past, and there is no contact lens provided with the sustained release of the drug which can be maintained for a sufficient time. Therefore, development of a method for manufacturing such a contact lens has been awaited.

[0006]

DISCLOSURE OF THE INVENTION The present invention has been made in view of the above-mentioned prior art, and is intended to provide a contact lens provided with a sustained drug release which can be maintained for a sufficient time regardless of its material, at a low cost. It is an object of the present invention to provide a simple and easy manufacturing method.

[0007]

SUMMARY OF THE INVENTION The present invention relates to a method for preparing a fine powder or gel of a drug from at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate. A method of preparing a contact lens for drug-controlled visual acuity correction, comprising preparing a drug release and adhering the drug sustained-release agent to a part of the contact lens; and a polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, The present invention relates to a fine powder or gel drug sustained-release agent used in the above-mentioned production method, wherein at least one polymer selected from dimethylacrylamide and sodium hyaluronate is dissolved in an aqueous solution of the drug.

[0008]

BEST MODE FOR CARRYING OUT THE INVENTION As described above, a method for producing a contact lens for sustained-release visual acuity correction of the present invention is selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate. A fine powder or gel drug sustained-release agent is prepared from at least one polymer, and the drug sustained-release agent is attached to a part of a contact lens.

In the present invention, since a drug sustained-release agent capable of imparting a drug sustained-release property to a contact lens is attached to a part of the contact lens, unlike a conventional contact lens material itself containing a drug, Regardless of the material, a contact lens provided with a sustained release of a drug that can be maintained for a sufficient time can be easily obtained. In addition, the drug sustained-release agent used is obtained by dissolving a polymer such as polyhydroxyalkyl (meth) acrylate in an aqueous solution of a desired drug, and thus has the advantage of being inexpensive.

In the production method of the present invention, first, a sustained-release drug is prepared.

[0011] The drug sustained-release agent is obtained, for example, by dissolving at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate in an aqueous drug solution. .

Among the above-mentioned polymers, typical examples of polyhydroxyalkyl (meth) acrylate include polyhydroxyethyl (meth) acrylate, polyhydroxypropyl (meth) acrylate and the like.

In this specification, "~ (meth) acryl ..." means "~ acryl ... and / or ...
Methacrylate ... ".

In the present invention, polyvinylpyrrolidone and sodium hyaluronate are particularly preferred among the above-mentioned polymers, because the solubility of various drugs in an aqueous solution is higher and a desired drug sustained-release agent can be easily prepared.

Further, the weight average molecular weight of the polymer is:
In order to sufficiently improve the feeling of wearing the finally obtained contact lens, it is desirable that the contact lens has a molecular weight of 10,000 or more, preferably 20,000 or more. In order to achieve this, no more than 2,000,000, preferably 100,000
It is desirably 0 or less.

The agent may be any agent as long as its aqueous solution can dissolve the polymer.
-104630, JP-B-59-7684,
General ophthalmic drugs such as preventive and therapeutic agents for eye diseases such as inflammation and wounds, diagnostic agents, immunosuppressants, and the like described in JP-T-7-503974 and the like. The general active ingredient can be used. Specific examples of such agents include, for example, tear-increasing agents, cell growth promoters, corneal thickness increase inhibitors, mydriatics, miotics, antibiotics, antibacterials, antihistamines, anti-inflammatory agents, anticholinergic agents And anti-glaucoma compounds, anti-viral agents, carbonic anhydrase inhibitors, anti-fungal agents, anesthetics, peptides, proteins and the like.

The ratio between the drug and the polymer when the solution is obtained by dissolving the polymer in the aqueous solution of the drug may be appropriately adjusted according to the type of the drug and the polymer used so as to obtain a uniform solution. Although there is no particular limitation, it is preferable that the concentration of the solution is, for example, about 0.5 to 10 w / v%.

The viscosity of the solution at 20 ° C. measured by a rotational viscometer should be 1 P or more, preferably 2 P, in order to sufficiently improve the wearing feeling of the contact lens finally obtained. It is preferably at least 100P, and more preferably at most 100P, preferably at most 90P, in order for the contact lens to exhibit excellent drug sustained release.

In order to prepare the fine powdered or gelled sustained-release drug of the present invention from the solution obtained as described above, for example, the solution is sprayed under reduced pressure to form a fine powder by a spray-drying method. A method of forming a powder can be employed.

The drug sustained-release agent of the present invention is in the form of a fine powder or a gel so that the drug sustained-release agent can easily adhere to a contact lens. Also,
When the drug sustained release agent is in the form of a fine powder, the average particle size is preferably about 15 μm or less, and among them, it is particularly preferable to use fine particles having a particle size of about 3 μm or less. However, if the contact lens is non-hydrous, it is difficult to fix the lens when attaching the drug sustained-release agent. Used.

Next, the drug sustained-release agent thus obtained is adhered to a part of the contact lens to obtain a drug sustained-release vision-correcting contact lens.

In the present invention, there is no particular limitation on the part to which the sustained release of the drug is adhered, as long as it is outside the lens optical region where the field of view is not obstructed when the contact lens is worn, but the feeling of wearing is further improved. From this point, it is preferable that the adhesive be attached to the peripheral portion of the lens.

In order to adhere the drug sustained-release agent to a part of the contact lens, for example, the drug sustained-release agent is directly applied to the contact lens, pressed or sprayed,
A method in which a contact lens is immersed in a drug sustained-release agent can be adopted.

[0024] The amount of the drug sustained-release agent adhered to the contact lens is not particularly limited as long as the drug sustained release property is sufficiently exhibited, and is not particularly limited. In order to achieve this, the adjustment may be made, for example, so as to be about 20 mg or less per contact lens.

In the present invention, the contact lens to which the sustained-release agent is adhered is not particularly limited. For example, a silicon-containing monomer, a fluorine-containing monomer, a hydroxyl-containing monomer, and a cross-linkable monomer which are usually used when obtaining a contact lens Contact lenses manufactured by a usual method using various monomers such as the above can be used without exception.

Thus, the contact lens for sustained-release visual acuity correction obtained by the production method of the present invention is one in which the drug is gradually released from the sustained-release agent adhered to a part of the contact lens over a sufficient period of time. It can be suitably used as an ophthalmic contact lens for treatment, diagnosis, immunosuppression and the like.

[0027]

Next, the method for producing the contact lens for sustained-release visual acuity correction according to the present invention and the sustained-release agent for use therein will be described in more detail with reference to Examples, but the present invention is limited to only these Examples. It is not something to be done.

Example 1 12 ml of a 1% aqueous carteolol hydrochloride solution as an ophthalmic solution
To polyvinylpyrrolidone (weight average molecular weight: 8000
0) 600 mg was dissolved to obtain a 5% w / v solution. The viscosity of the solution at 20 ° C. was 5P.

Next, a fine powdery sustained-release agent having an average particle diameter of about 10 μm was prepared from the above solution by a spray drying method. After that, air is blown up and the particle size becomes 3μ.
Only the fine particles of m or less were classified.

Further, a part of the extracted microparticles having a particle diameter of 3 μm or less is partially added to a part of the outer periphery of a soft contact lens “MENICON SOFT MA” (trade name) manufactured by Menicon Corporation.
mg was manually applied and adhered. The attached fine particles quickly absorbed water and became a gel.

The contact lens to which the fine particles were attached was worn on rabbit eyes, and its intraocular pressure was measured 36 hours later. The intraocular pressure was lower than before wearing, and the sustained release was maintained for a long time. I was

Example 2 Into 8 ml of a 1% aqueous solution of carteolol hydrochloride as an ophthalmic solution,
Sodium hyaluronate (weight average molecular weight: 80000)
0) 80 mg was dissolved to obtain a gel-like 1 w / v% solution. The viscosity at 20 ° C. of the solution was 10P.

Next, one end (bottom surface) has a hole diameter of 10 mm.
The solution was placed in a cylindrical container having a nylon mesh of μm.

Further, a contact lens “MENICON EX” (trade name) manufactured by Menicon Co., Ltd.
Approximately 10 solutions (gel release agent) from the cylindrical container
mg was extruded and deposited.

The contact lens to which the gel-like drug sustained-release agent was attached was worn on rabbit eyes, and its intraocular pressure was measured after 36 hours. For a long time.

[0036]

According to the production method of the present invention, a sustained drug release that can be maintained for a sufficient time is imparted regardless of its material,
In addition, it is possible to easily produce a contact lens for drug sustained release eyesight correction with improved wearing feeling.

Therefore, the contact lens for sustained-release visual acuity correction obtained by the above-mentioned manufacturing method can be suitably used as an ophthalmic contact lens for various prevention, treatment, diagnosis, immunosuppression and the like.

The sustained-release drug used in the above-mentioned production method has an advantage of being inexpensive.

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁶ Identification code FI C08L 39/06 C08L 39/06

Claims (5)

[Claims] 1. A fine powder or gel drug sustained-release agent is prepared from at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate. A method for producing a drug sustained-release vision-correcting contact lens, characterized in that a sustained-release agent is attached to a part of the contact lens. 2. The method according to claim 1, wherein the polymer is dissolved in an aqueous solution of a drug, and a sustained-release drug is prepared from the obtained solution. 3. The weight average molecular weight of the polymer is 10,000.
3. The method for producing a drug sustained-release visual acuity correcting lens according to claim 1 or 2, which has a molecular weight of up to 2,000,000. 4. The method for producing a drug according to claim 2, wherein the solution has a viscosity at 20 ° C. of 1 to 100 P. 5. The method according to claim 1, wherein at least one polymer selected from polyhydroxyalkyl (meth) acrylate, polyvinylpyrrolidone, polydimethylacrylamide and sodium hyaluronate is dissolved in an aqueous solution of a drug. A sustained-release agent in the form of a fine powder or a gel used in the production method described above.